Compounds > mn(iii) 5,10,15,20-tetrakis(n-methylpyridinium-2-yl)porphyrin
Page last updated: 2024-09-04

mn(iii) 5,10,15,20-tetrakis(n-methylpyridinium-2-yl)porphyrin and interleukin-8

mn(iii) 5,10,15,20-tetrakis(n-methylpyridinium-2-yl)porphyrin has been researched along with interleukin-8 in 1 studies

Compound Research Comparison

Studies
(mn(iii) 5,10,15,20-tetrakis(n-methylpyridinium-2-yl)porphyrin)		Trials
(mn(iii) 5,10,15,20-tetrakis(n-methylpyridinium-2-yl)porphyrin)		Recent Studies (post-2010)
(mn(iii) 5,10,15,20-tetrakis(n-methylpyridinium-2-yl)porphyrin)		Studies
(interleukin-8)		Trials
(interleukin-8)		Recent Studies (post-2010) (interleukin-8)
6904223,5231,1679,990

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Alferiev, IS; Chorny, M; Greineder, CF; Hood, ED; Howard, MD; Muzykantov, V1

Other Studies

1 other study(ies) available for mn(iii) 5,10,15,20-tetrakis(n-methylpyridinium-2-yl)porphyrin and interleukin-8

ArticleYear
Targeting to endothelial cells augments the protective effect of novel dual bioactive antioxidant/anti-inflammatory nanoparticles.
    Molecular pharmaceutics, 2014, Jul-07, Volume: 11, Issue:7

    Topics: Anti-Inflammatory Agents; Antioxidants; Cells, Cultured; E-Selectin; Endothelial Cells; Human Umbilical Vein Endothelial Cells; Humans; Inflammation; Interleukin-8; Metalloporphyrins; Nanoparticles; Oxidative Stress; Particle Size; Superoxide Dismutase; Vascular Cell Adhesion Molecule-1

2014